DewDiligence Friday, 04/24/20 12:51:00 PM Re: None Post # of 544 MRK/AZN—Lynparza shows statsig-superior OS to hormonal agents (Xtandi, Zytiga) in the phase-3 PROFOUND study in second-line CRPC with certain genetic mutations: https://www.businesswire.com/news/home/20200424005205/en Lynparza is the only PARP inhibitor to show an OS benefit in this setting. The PROFOUND study met its primary endpoint of radiographic PFS in Aug 2019, and the resulting NDA and MAA are currently under FDA and EMA review. A trial of Lynparza in first-line CRPC is in progress with results expected in 2021. “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”